Maxim Group set a $5.00 price objective on Anavex Life Sciences (NASDAQ:AVXL) in a research note published on Wednesday, February 14th. The firm currently has a buy rating on the biotechnology company’s stock.
A number of other research analysts have also issued reports on AVXL. Noble Financial restated a buy rating on shares of Anavex Life Sciences in a research report on Tuesday, December 12th. ValuEngine lowered Anavex Life Sciences from a hold rating to a sell rating in a research report on Tuesday, November 21st.
Anavex Life Sciences (AVXL) traded down $0.03 during trading hours on Wednesday, reaching $2.49. The company had a trading volume of 136,000 shares, compared to its average volume of 307,965. Anavex Life Sciences has a twelve month low of $2.45 and a twelve month high of $6.49. The firm has a market cap of $110.99, a price-to-earnings ratio of -7.35 and a beta of 0.88.
Anavex Life Sciences (NASDAQ:AVXL) last released its quarterly earnings data on Wednesday, February 7th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter. research analysts expect that Anavex Life Sciences will post -0.42 earnings per share for the current fiscal year.
A number of hedge funds have recently made changes to their positions in the business. Millennium Management LLC boosted its position in Anavex Life Sciences by 95.2% during the 4th quarter. Millennium Management LLC now owns 44,895 shares of the biotechnology company’s stock worth $145,000 after acquiring an additional 21,895 shares during the period. Deutsche Bank AG boosted its position in Anavex Life Sciences by 150.9% during the 4th quarter. Deutsche Bank AG now owns 82,967 shares of the biotechnology company’s stock worth $266,000 after acquiring an additional 49,904 shares during the period. Bank of New York Mellon Corp boosted its position in Anavex Life Sciences by 60.3% during the 4th quarter. Bank of New York Mellon Corp now owns 177,938 shares of the biotechnology company’s stock worth $573,000 after acquiring an additional 66,931 shares during the period. Wells Fargo & Company MN boosted its position in Anavex Life Sciences by 40.8% during the 3rd quarter. Wells Fargo & Company MN now owns 56,873 shares of the biotechnology company’s stock worth $236,000 after acquiring an additional 16,488 shares during the period. Finally, SNS Financial Group LLC acquired a new position in Anavex Life Sciences during the 3rd quarter worth $290,000. Institutional investors own 22.68% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Anavex Life Sciences (NASDAQ:AVXL) PT Set at $5.00 by Maxim Group” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another website, it was stolen and reposted in violation of U.S. and international copyright and trademark legislation. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/02/23/anavex-life-sciences-avxl-given-a-5-00-price-target-by-maxim-group-analysts.html.
About Anavex Life Sciences
Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.
Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.